Ecto-5'-nucleotidase (CD73)-mediated formation of adenosine is critical for the striatal adenosine A2A receptor functions

• Published in: The Journal of neuroscience Vol. 33; no. 28; pp. 11390 - 11399
• Main Authors: Augusto, Elisabete, Matos, Marco, Sévigny, Jean, El-Tayeb, Ali, Bynoe, Margaret S, Müller, Christa E, Cunha, Rodrigo A, Chen, Jiang-Fan
• Format: Journal Article
• Language: English
• Published: United States Society for Neuroscience 10.07.2013
• Subjects: 5'-Nucleotidase - physiology; Adenosine - metabolism; Adenosine A2 Receptor Antagonists - pharmacology; Animals; Corpus Striatum - drug effects; Corpus Striatum - physiology; Female; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Pyrimidines - pharmacology; Receptor, Adenosine A2A - physiology; Triazoles - pharmacology
• ISSN: 0270-6474; 1529-2401; 1529-2401
• DOI: 10.1523/jneurosci.5817-12.2013

Adenosine is a neuromodulator acting through inhibitory A1 receptors (A1Rs) and facilitatory A2ARs, which have similar affinities for adenosine. It has been shown that the activity of intracellular adenosine kinase preferentially controls the activation of A1Rs, but the source of the adenosine activating A2ARs is unknown. We now show that ecto-5'-nucleotidase (CD73), the major enzyme able to convert extracellular AMP into adenosine, colocalizes with A2ARs in the basal ganglia. In addition to astrocytes, striatal CD73 is prominently localized to postsynaptic sites. Notably, CD73 coimmunoprecipitated with A2ARs and proximity ligation assays confirmed the close proximity of CD73 and A2ARs in the striatum. Accordingly, the cAMP formation in synaptosomes as well as the hypolocomotion induced by a novel A2AR prodrug that requires CD73 metabolization to activate A2ARs were observed in wild-type mice, but not in CD73 knock-out (KO) mice or A2AR KO mice. Moreover, CD73 KO mice displayed increased working memory performance and a blunted amphetamine-induced sensitization, mimicking the phenotype of global or forebrain-A2AR KO mice, as well as upon pharmacological A2AR blockade. These results show that CD73-mediated formation of extracellular adenosine is responsible for the activation of striatal A2AR function. This study points to CD73 as a new target that can fine-tune A2AR activity, and a novel therapeutic target to manipulate A2AR-mediated control of striatal function and neurodegeneration.